{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:55:13Z","timestamp":1781801713800,"version":"3.54.5"},"reference-count":30,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Skin Pharmacol Physiol"],"abstract":"<jats:p>Introduction: Skin cancer is a growing global health concern, often linked to environmental carcinogens like ultraviolet radiation and chemicals. This study investigated the protective effects of sakuranetin against DMBA-induced skin cancer in mice. Methods: A total of 24 mice were randomly divided into four groups: a control group, a disease control group, and two treatment groups that received sakuranetin orally at 10 mg\/kg and 20 mg\/kg post-DMBA exposure for 8 weeks. Tumorigenesis was evaluated through histopathology, followed by hematological (HB, RBCs, MCV, WBCs, PCV, and MCH), antioxidant enzyme levels (SOD, CAT, GSH), lipid peroxidation, pro-inflammatory markers (IL-1\u03b2, IL-6, TNF-\u03b1, COX-2), NF-\u03baB, and caspase-3. Additionally, network pharmacology and molecular docking were performed. Results: Treatment with sakuranetin restored the abnormal hematological parameters, restored antioxidant enzyme levels (SOD, CAT, GSH), reduced lipid peroxidation, and significantly reduced pro-inflammatory markers, NF-\u03baB, while increased caspase-3. Histological examination confirmed reduced neoplastic changes. Sakuranetin at the dose of 20 mg\/kg completely prevents tumor development. Network pharmacology identified 53 potential sakuranetin targets, and molecular docking revealed strong binding affinities with key proteins, including COX-2 (\u22129.2), TGF-\u03b2 (\u22128.5), NF-\u03baB (\u22128.1), caspase-3 (\u22126.8), and VEGF (\u22125.9), which are involved in cancer pathways. Conclusion: Sakuranetin effectively mitigated DMBA-induced skin cancer through antioxidant, anti-inflammatory, and pro-apoptotic mechanisms. These findings suggest its potential as a multi-targeted therapeutic candidate for skin cancer prevention.<\/jats:p>","DOI":"10.1159\/000551641","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:01:22Z","timestamp":1775836882000},"page":"1-14","source":"Crossref","is-referenced-by-count":1,"title":["Network Pharmacology, Molecular Docking, Hematological Evaluation, and in vivo Evidence Support Sakuranetin as a Redox and Inflammation-Modulating Agent against Skin Tumorigenesis"],"prefix":"10.1159","author":[{"given":"Humood","family":"Al Shmrany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkarim S.","family":"Binshaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01854-3"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11042-018-5714-1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6010006"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.57239\/pjlss-2024-22.2.0056"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01708-4"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2024.2325659"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156540"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3881\/j.issn.1000-503X.16087"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116194"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00444.2015"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.12.071"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26216590"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0076-6879(84)05016-3"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1042\/bj0990667"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2020.166747"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.53388\/pd202404004"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2024.08.002"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-019-04920-w"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2015.16.6.2303"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.13005\/bpj\/2852"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8127362"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/194482"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.22159\/ajpcr.2022.v15i11.45615"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00351"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1366"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.5650\/jos.ess21055"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-020-00349-0"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4103\/pm.pm_152_21"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.07.050"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.6026\/97320630017363"}],"container-title":["Skin Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000551641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:01:14Z","timestamp":1781798474000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000551641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1159\/000551641","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.31971570","asserted-by":"subject"}]},"ISSN":["1660-5527","1660-5535"],"issn-type":[{"value":"1660-5527","type":"print"},{"value":"1660-5535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}